Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 24.68
- Piotroski Score 5.00
- Grade Buy
- Symbol (SLP)
- Company Simulations Plus, Inc.
- Price $29.48
- Changes Percentage (6.87%)
- Change $1.9
- Day Low $27.76
- Day High $29.63
- Year High $51.22
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
- Last Earnings 07/02/2024
- Ex-Dividend for 5/16 Dividend 07/29/2024
- Dividend Payable 08/05/2024
- Today N/A
- Next Earnings (Estimated) 01/08/2025
- Fiscal Year End N/A
- Average Stock Price Target $56.00
- High Stock Price Target $65.00
- Low Stock Price Target $47.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.52
- Trailing P/E Ratio 88.88
- Forward P/E Ratio 88.88
- P/E Growth 88.88
- Net Income $9.95 M
Income Statement
Quarterly
Annual
Latest News of SLP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SLP Resources Berhad's (KLSE:SLP) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?
SLP Resources Berhad's stock has risen by 2.3% in three months, yet financials seem unpromising. Focus is on ROE, indicating the company's efficiency in generating profits and growth potential....
By Yahoo! Finance | 2 weeks ago -
Simulations Plus Inc (SLP) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market ...
Shawn O'Connor, CEO of the company, addressed the impact of attrition rates on profitability in Q3 and Q4, leading to adjusted recruiting plans for 2025. Pro-ficiency's competitive position is strong ...
By Yahoo! Finance | 4 weeks ago -
Simulations Plus (SLP) Fell Due to EBITDA Below Expectations
Conestoga Capital Advisors reported a strong performance in Q3 2024, with their small and mid-cap composites outperforming respective indices. They highlighted Simulations Plus, Inc. (NASDAQ:SLP) for ...
By Yahoo! Finance | 4 weeks ago
